Ask for a quote on the same compound at the same nominal mass from several sources and the spread can be three-fold or more. Some of that spread reflects real differences in what is in the vial. Some of it reflects nothing but margin. This article breaks the price of a research peptide into its actual components so the comparison can be made on something other than the headline figure.
Sequence length and the number of coupling steps
Solid-phase synthesis builds a chain one residue at a time, and every residue added is a separate chemical step with its own reagents, solvents and washes. A seven-residue peptide takes seven of those steps. A thirty-nine residue peptide takes thirty-nine. Worse, the yield compounds: if each step runs at 99 percent efficiency, a short peptide finishes near 93 percent of theoretical while a long one finishes near 68 percent, before purification losses. That is why cost per milligram climbs steeply with length rather than proportionally. The mechanics are covered in solid-phase peptide synthesis explained.
Lipidation and unusual residues
Standard L-amino acids are commodity inputs. Everything else is not. D-amino acids, non-natural residues such as alpha-aminoisobutyric acid, and naphthylalanine derivatives cost several times more per gram than their common counterparts. Attaching a fatty diacid chain through a linker, as in retatrutide, adds its own steps with their own protecting group chemistry and their own failure modes. Cyclisation, disulfide bridges and metal complexation each add a stage after the chain is assembled. None of this is visible on the label, and all of it is in the price.
Purification effort to reach 99 percent
The crude product coming off the resin is a mixture: the target sequence plus deletion sequences, incompletely deprotected chains, and oxidation products. Getting from crude to 95 percent purity is routine. Getting from 95 to 99 percent means preparative chromatography with narrower collection windows, which means throwing away fractions that contain real product. The last few percentage points of purity are bought with yield, and yield is mass you paid to synthesise and cannot sell. A vendor quoting 99 percent has either done that work or has not measured carefully.
Third-party testing, per lot
Independent HPLC and mass spectrometry on every lot is a recurring per-lot cost, not a one-time expense. A vendor testing one lot in ten, or reusing an old certificate across new production, has a structurally lower cost base than one testing everything. That difference shows up as a lower shelf price and as an unverifiable claim. The checks that separate the two are in how to spot a bad peptide vendor.
Net peptide content: the cheaper vial may hold less peptide
This is the single most common way an apples-to-apples comparison goes wrong. Lyophilized powder is never pure peptide by weight. It carries bound water and counter-ions, commonly trifluoroacetate left from purification. Net peptide content is the fraction of the powder's mass that is actually peptide, and it typically runs somewhere in the eighty to ninety percent range depending on the compound and the process.
A 10 mg vial at 90 percent net content holds 9 mg of peptide. The same nominal vial at 70 percent holds 7 mg. That is a 29 percent difference in material for an identical label, and net content is reported only by vendors who measure it. Purity and net content answer different questions, as set out in net peptide content versus purity.
Lyophilization, vials and fill
Freeze-drying is slow and equipment-intensive, and the cost is driven by run time and shelf space rather than by the mass on the shelf. Filling a hundred 5 mg vials costs far more than filling ten 50 mg vials holding the same total material, because the per-vial costs, the glass, the stopper, the crimp, the fill step, the inspection, are identical regardless of what is inside. This is the mechanical reason price per milligram falls as vial size rises.
Domestic versus imported supply
Material synthesised and finished domestically carries higher labour and facility costs than material sourced through a long import chain, and it carries shorter, more auditable provenance. An imported bulk powder repackaged into vials near the point of sale can be genuinely cheap and can also be genuinely good, but the chain between synthesis and vial is longer and harder to verify. Our position on that trade-off is set out in why USA-made matters for research peptides.
A worked comparison, at our current list prices
The table below uses our own catalogue. It shows the within-compound effect of vial size, which is the cleanest signal in peptide pricing.
| Compound | Vial | List price | Price per mg |
|---|---|---|---|
| BPC-157 | 5 mg | $60 | $12.00 |
| BPC-157 | 10 mg | $80 | $8.00 |
| BPC-157 | 15 mg | $100 | $6.67 |
| TB-500 | 10 mg | $100 | $10.00 |
| Retatrutide | 10 mg | $105 | $10.50 |
| Retatrutide | 30 mg | $240 | $8.00 |
| Retatrutide | 60 mg | $400 | $6.67 |
Two things to read from it. Within a compound, per-milligram cost drops by roughly forty percent from the smallest vial to the largest, which is the fill and finish effect described above. Across compounds it does not track length neatly: TB-500 is a seven-residue acetylated fragment and sits above BPC-157's fifteen residues per milligram at the same vial size, because purification behaviour, demand and fill volume all pull on the number too. Prices are current at publication and change with input costs. The size decision itself is covered in choosing the right vial size, and the full range sits in our best sellers collection.
What a suspiciously low price usually means
- Low or unstated net peptide content. The cheapest way to sell a 10 mg vial is to put less than 10 mg of peptide in it.
- Purity measured generously. Detection at 280 nm rather than 214 nm, or an overloaded column, both flatter the number.
- Testing amortised across lots. One certificate covering many production runs costs almost nothing and proves almost nothing.
- Underfill on the mass itself. Fill weight variation is invisible without a balance and a certificate that states it.
- No identity confirmation. Mass spectrometry is the only routine check that the vial holds the compound named on it, and it is the first test to disappear when costs are cut.
Frequently asked questions
Is a more expensive peptide always purer?
No. Price correlates with input cost and with testing rigour, not with quality by itself. The certificate is the evidence; the price is only a signal. A high price with no lot-matched certificate proves nothing at all.
Why do blends sometimes cost less than the components separately?
A co-lyophilized blend is one vial, one fill, one stopper and one lyophilization run rather than two. The per-vial overheads are shared, so the combined product can list below the sum of its parts while containing the same total material.
How should two vendors be compared fairly?
Convert both to price per milligram of actual peptide, using net peptide content from each certificate rather than the label mass. Then confirm both purity figures were measured by the same method at the same wavelength. If either vendor cannot supply that information, the comparison cannot be made.
References
- Merrifield RB. 1963. Solid phase peptide synthesis I: the synthesis of a tetrapeptide. Journal of the American Chemical Society.
- Behrendt R, White P, Offer J. 2016. Advances in Fmoc solid-phase peptide synthesis. Journal of Peptide Science.
- Isidro-Llobet A, et al. 2019. Sustainability challenges in peptide synthesis and purification: from R and D to production. Journal of Organic Chemistry.
- Mant CT, et al. 2007. HPLC analysis and purification of peptides. Methods in Molecular Biology.
Research use only. This article discusses the economics of laboratory reagents. Homegrown Peptides products are not for human or animal use, are not drugs, and are not intended to diagnose, treat, cure or prevent any disease. Nothing here is medical advice.
